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Abstract
Background: Prostaglandin E2 (PGE2)-involved neuroinflammatory processes are prevalent in several neurological
conditions and diseases. Amyloid burden is correlated with the activation of E-prostanoid (EP) 2 receptors by
PGE2 in Alzheimer’s disease. We previously demonstrated that electromagnetic field (EMF) exposure can induce
pro-inflammatory responses and the depression of phagocytosis in microglial cells, but the signaling pathways
involved in phagocytosis of fibrillar β-amyloid (fAβ) in microglial cells exposed to EMF are poorly understood.
Given the important role of PGE2 in neural physiopathological processes, we investigated the PGE2-related
signaling mechanism in the immunomodulatory phagocytosis of EMF-stimulated N9 microglial cells (N9 cells).
Methods: N9 cells were exposed to EMF with or without pretreatment with the selective inhibitors of
cyclooxygenase-2 (COX-2), Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3), and
mitogen-activated protein kinases (MAPKs) and antagonists of PG receptors EP1-4. The production of endogenous PGE2
was quantified by enzyme immunoassays. The phagocytic ability of N9 cells was evaluated based on the fluorescence
intensity of the engulfed fluorescent-labeled fibrillar β-amyloid peptide (1-42) (fAβ42) measured using a flow cytometer
and a fluorescence microscope. The effects of pharmacological agents on EMF-activated microglia were investigated
based on the expressions of JAK2, STAT3, p38/ERK/JNK MAPKs, COX-2, microsomal prostaglandin E synthase-1
(mPGES-1), and EP2 using real-time PCR and/or western blotting.
Results: EMF exposure significantly increased the production of PGE2 and decreased the phagocytosis of
fluorescent-labeled fAβ42 by N9 cells. The selective inhibitors of COX-2, JAK2, STAT3, and MAPKs clearly depressed
PGE2 release and ameliorated microglial phagocytosis after EMF exposure. Pharmacological agents suppressed the
phosphorylation of JAK2-STAT3 and MAPKs, leading to the amelioration of the phagocytic ability of EMF-stimulated N9
cells. Antagonist studies of EP1-4 receptors showed that EMF depressed the phagocytosis of fAβ42 through the PGE2
system, which is linked to EP2 receptors.
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Conclusions: This study indicates that EMF exposure could induce phagocytic depression via JAK2-STAT3- and
MAPK-dependent PGE2-EP2 receptor signaling pathways in microglia. Therefore, pharmacological inhibition of
PGE2 synthesis and EP2 receptors may be a potential therapeutic strategy to combat the neurobiological deterioration
that follows EMF exposure.
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Background
Electromagnetic field (EMF) exposure has been acceler-
ated by technological advancements [1], increasing the
health risks associated with neurological disorders, such
as gliomas [2, 3] and Alzheimer’s disease (AD) [4, 5]. It
is widely accepted that most cases of AD are associated
with persistent inflammation and decreased clearance and
degradation of amyloid beta (Aβ) [6, 7]. Additional evidence
has revealed that pro-inflammatory cytokines act selectively
to regulate the different types of microglial phagocytosis
[8]. We previously observed pro-inflammatory responses
and a depression of phagocytic activity in EMF-stimulated
N9 microglial cells (N9 cells) [9]. However, it remains a
central challenge to determine which special cytokines in-
hibit microglial Aβ clearance after EMF exposure.
Recent evidence confirmed the role of microglial pro-
inflammatory responses in the development of AD [10].
Among the most important mediators of the prominent
and rapid induction of the AD in the brain are cyclooxy-
genase 2 (COX-2) and prostaglandins [6, 11]. In particu-
lar, PGE2 is of interest in the development of AD, as it is
initially significantly elevated in patients with very early
stage or probable AD [12, 13]. Certain studies have shown
that prostaglandin E2 (PGE2) mediates the potentiation of
inflammatory responses and amyloid plaque formation
[11, 14]. PGE2 can exert both detrimental and beneficial
effects through four G-protein-coupled receptors named
E-prostanoid (EP)1, EP2, EP3, and EP4 [15]. Among these,
EP2 signaling is associated with pro-inflammatory gene
up-regulation, the inhibition of beneficial chemokine pro-
duction, and Aβ clearance underlying aging and/or Aβ42
accumulation [16]. Moreover, it has been revealed that
PGE2 attenuates phagocytosis of latex beads by fibrillar
β-amyloid peptide (1-42) (fAβ42)-stimulated microglia
via the downstream EP2/protein kinase A (PKA) pathway
[17, 18]. However, upstream pathways of PGE2 might also
be important. Although much effort has been dedicated to
identifying the upstream targets of COX-2-PGE2 cascades
in microglia [19–22], the exact synthesis mechanisms of
PGE2 underlying the salutary effect of EMF on microglial
phagocytosis in AD remain largely unknown.
PGE2 plays an important role in the modulation of
immune responses and inflammatory processes [23].
Three types of PGE synthases (PGESs) that participate in
the synthesis of PGE2 have been described: one cytosolic
PGES and two membrane-associated PGESs, microsomal
PGES-1 and PGES-2 [24, 25]. Positive feedback by PGE2 on
COX-2 and mPGES-1 expressions was previously observed
and has received marked attention [26–28]. Recent evidence
revealed the signaling pathways of the different regulation
mechanisms of mPGES-1 and COX-2 and/or PGE2 release
in primary activated rat microglia, involving protein kinase C
(PKC), phosphatidylinositol 3-kinase (PI3K), IkB kinase
(IKK)2, nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), and mitogen-activated protein
kinases (MAPKs) [19, 21]. Additionally, LPS-stimulated
PGE2 release from spinal microglia is dependent on in-
creases in COX-1 and/or COX-2 activity regulated by p38
MAPK activation [20]. In contrast, evidence from astro-
cytic cells has indicated a toxic role of Aβ42 in AD via a
NF-κB-dependent mechanism [29]. In addition to these
findings, the Janus kinase 2 (JAK2)/signal transducer and
activator of transcription 3 (STAT3) pathway has also been
reported to be involved in the inhibition of PGE2 production
in BV-2 microglial cells [22]. We previously demonstrated a
profound increase in the activated forms of JAK2 and
STAT3 in EMF-stimulated N9 cells [30, 31]. These observa-
tions suggest that pharmacological inhibition of the JAK2-
STAT3 and MAPK pathways in microglia may be a helpful
approach in addressing the aforementioned questions.
Recent evidence suggests that an efficacious strategy
against AD may be the promotion of phagocytosis and
the inhibition of pro-inflammatory responses in microglia.
Given the intricately intertwined role of microglia with the
intracellular pathways involved in PGE2 production, in this
study, we utilized a series of pharmacological approaches to
investigate the molecular mechanisms that regulate Aβ42
phagocytosis-associated PGE2 synthesis in EMF-stimulated
N9 cells. We demonstrated that JAK2-STAT3- and MAPK-
dependent PGE2 synthesis are, at least in part, responsible
for defective phagocytosis in EMF-stimulated microglial
cells. The pharmacologic outcomes may provide critical
information for targeting the microglial PGE2 synthesis
in neurologic disorders that is associated with defective
phagocytosis.
Methods
Cell culture and treatment
The immortalized murine microglial N9 cells were a gift
from Dr. Yun Bai (Department of Genetics, Third Military
He et al. Journal of Neuroinflammation  (2016) 13:296 Page 2 of 14
Medical University, China) and were originally established
by immortalization of day 13 embryonic brain cultures
with the 3RV retrovirus carrying an activated v-myc
oncogene [32, 33]. Cells were grown in Iscove’s modi-
fied Dulbecco’s medium (IMDM; HyClone, Logan, UT,
USA) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS; HyClone), 2 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 50 μM 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA).
The cells were seeded in 25-cm2 T-flasks (5 × 106 cells/
flask), 6-well plates (5 × 105 cells/well), and 24-well
plates (1.5 × 105 cells/well) at 37 °C in a humidified 5%
CO2 atmosphere. N9 cells were passaged every 3 days
at a 1:4 split ratio, and passages were used after 3–10
passages. After 24-h incubation, the cell culture medium
was replaced with serum-free IMDM supplemented with
or without the compounds of interest and incubated for
30 min prior to EMF stimulation. Then, cells were sub-
jected to a 1-h process of phagocytosis 3 or 12 h after EMF
exposure. Pharmacologic agents were purchased from
Sigma-Aldrich unless otherwise indicated and were used in
different experiments that included COX-2 inhibitor
celecoxib (1, 5, 25 μM), JAK2 inhibitor AG490 (25 μM),
STAT3 inhibitor S3I-201 (30 μM), p38 inhibitor SB203580
(10 μM), mitogen-activated protein kinase (MEK)-
extracellular signal-regulated kinase (ERK) (MEK1/2-
ERK1/2) inhibitor PD98059 (30 μM), c-Jun N-terminal
kinase (JNK) inhibitor SP600125 (5 μM), antagonists of
PG receptors EP1-4 (GW848687X (5 μM), AH6809
(10 μM), L-798106 (10 μM), GW627368X (10 μM;
Cayman Chemical, Ann Arbor, MI, USA)), and a solvent
control (tissue culture-grade dimethylsulfoxide (DMSO,
0.2%)). Doses of pharmacologic agents were chosen based
on prior specificity studies and were shown to not alter
the growth characteristics of N9 cells. None of the
compounds displayed toxic or cytostatic effects in vitro at
the corresponding concentration used in our experi-
mental conditions (Additional file 1: Figure S1).
Cell viability
N9 cells were indirectly assessed for cell viability using
proliferation-based Cell Counting Kit-8 assay (CCK-8;
Dojindo, Shanghai, China) 24 h after EMF exposure and
aforementioned compounds treatment. Briefly, at the
end of the culture period, 10 μl of CCK-8 solution was
added to each well of the culture plate. After a 2-h
incubation at 37 °C, absorbance at 450 nm was measured
with a plate reader (BioTek Epoch, Winooski, VT, USA).
A control was performed in parallel to monitor the
influence of IMDM medium on the assays. Cell viability
was expressed as a percentage of the control cell culture
value using the following formula: cell viability = (absorp-
tion of sample − absorption of background)/(absorption of
control − absorption of background) × 100%.
Exposure system
As previously described, 2.45-GHz-pulsed microwaves,
widely used in household appliances, medical applica-
tions, and communication systems, were employed [31].
Briefly, an EMF pulse was delivered through a rectangu-
lar horn antenna connected horizontally to a handset
(Philips PM 7320X, Sivers IMA, Kista, Sweden). This
system was set to deliver 90 mW through the handset.
The pulse width was 2 μs, and the pulse repetition rate
was 500 pulses per second. The cells were exposed to
2.45-GHz-pulsed microwaves for 20 min at an average
specific absorption rate of 6 W/kg. During the 20-min
exposure period, the handset was held over the
culture layer of the flasks at a distance of 90 cm. For
EMF exposure, the flasks were placed in the upper
chamber of a PerspexTM water bath (24.5 × 21 cm). The
temperature of the medium in the flasks in the upper
chamber was maintained at 37 °C by circulating heated
water through a lower closed chamber. During sham
exposure, flasks were placed in the same conditions but
without EMF exposure.
Phagocytosis assay
Phagocytosis was determined with fluorescent-labeled
Aβ42 as previously described with slight modifications
[17]. In brief, HiLyteTM Fluor 647-labeled β-amyloid
peptide (1-42) (AnaSpec, San Jose, CA, USA) was
incubated at 37 °C for 7 days in a medium to promote fibril
formation (647-fAβ42). Then, the 647-fAβ42 was diluted to
0.1 μg/ml with the medium and applied to N9 cells after
the post-stimulation period (3 or 12 h) for either sham or
EMF exposure. After 1-h incubation, a washing step with a
cold serum-free medium was performed to interrupt
any interaction between phagocytosing microglia and
uningested 647-fAβ42. The phagocytic ability of the N9
cells was evaluated based on the fluorescence intensity
of the engulfed 647-fAβ42 measured using a flow
cytometer and fluorescence microscopy. In the
fluorescence-activated cell sorting (FACS) analysis, the
cells were collected and washed three times with ice-
cold phosphate-buffered saline (PBS) and resuspended
in 250 μl ice-cold PBS. The cell suspension was applied
to a FACSVerse™ flow cytometer (BD Biosciences, San
Jose, CA, USA).
For the morphological phagocytosis analysis, round
glass cover slips were placed in the wells of 24-well plates
before seeding N9 cells. Upon completion of phagocytosis,
the glass cover slips were carefully taken out of the
wells and rinsed twice in PBS. After being fixed and
permeabilized, the cells were blocked with goat serum
(Zhongshan Golden Bridge Biotechnology (ZsBio), Beijing,
China) for 20 min at room temperature and washed three
times in PBS. To label the membranes, cells were incu-
bated with both the primary rat anti-mouse monoclonal
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antibody CD11b (1:200; AbD Serotec, Oxford, UK) and
goat anti-rat Alexa Fluor 488 secondary antibody (1:500;
Life Technologies, Carlsbad, CA) for 1 h at 37 °C with an
interval step of three times wash. After washing and
mounting, phagocytosis and microglial marker CD11b
were visualized using a LSM 780 confocal laser scanning
microscope (Carl Zeiss GmbH, Jena, Germany). Image
analysis was performed based on a semi-quantitative
method. Fluorescence intensity was measured using
ImageJ 1.49 software.
Enzyme immunoassay (EIA) of PGE2 and TNF-α
Cells were seeded in 6-well plates. After pharmacologic
treatment and a 20-min EMF exposure of N9 cells in a
culture medium, cell culture supernatants were collected
and stored at −80 °C until use for detecting the level of
PGE2 and TNF-α. The cells were washed three times
with ice-cold PBS and resuspended in 100 μl ice-cold
PBS. Ten-microliter aliquots of the cell collections were
quantified using a cell counter (TC20, Bio-Rad, Hercules,
CA, USA). PGE2 and TNF-α levels were quantified
using an EIA kit (Cayman Chemical) and an ELISA kit
(eBioscience, San Diego, CA, USA), respectively, according
to the manufacturers’ instructions.
Nitric oxide (NO) determination
The production of NO metabolites (nitrates and nitrites)
in the culture medium was quantified using a NO detec-
tion kit (Nanjing Jiancheng Bioengineering Institute,
Nanjing, China). Briefly, 100 μl of medium was added to
each well. Then, 50 μl of nicotinamide adenine dinucleo-
tide and nitrate reductase was added to each well. After
30 min, Griess reagents I and II (both 50 μl) were added
and incubated for 10 min at room temperature. The op-
tical density of each well was determined using a micro-
plate reader with an emission wavelength at 540 nm.
Quantitative real-time polymerase chain reaction
Cells were seeded in 6-well plates. After treatment, total
RNA was isolated using TRIzol® regent (1 ml/well; Invitro-
gen, Carlsbad, CA, USA). RNA was reverse-transcribed
using 1 μg total RNA and an oligo-dT primer using a Pri-
meScript™ RT reagent kit with a gDNA Eraser comple-
mentary DNA (cDNA) synthesis kit according to the
manufacturer’s protocol (Takara Biotechnology, Dalian,
China). Real-time quantitative RT-PCR analysis was per-
formed using a Bio-Rad CFX Connect™ Real-Time PCR
Detection System (Bio-Rad) and a KAPA SYBR® FAST
qPCR kit (Kapa Biosystems, Boston, MA, USA). One-half
microliter of cDNA of each sample and 0.2 μM of each
primer were mixed in 20-μl reactions. Primers, mouse
COX-2 [NM_011198.3] forward 5′- GCTGGCCTGGTAC
TCAGTAGGTT -3′ and reverse 5′- CGAGGCCACTGA
TACCTATTGC -3′, mPGES-1 [NM_022415.3] forward
5′- ACGACATGGAGACAATCTATCCT -3′ and reverse
5′- TGAGGACAACGAGGAAATGT -3′, and EP2
[NM_008964.4] forward 5′- CCTTGGGTCTTTGCCAT
ACT -3′ and reverse 5′- GCACTGGACTGGGTAGAA
CAG -3′ were designed and synthesized by Sangon Bio-
tech Co., Ltd. (Shanghai, China). Primers hypoxanthine
phosphoribosyl-transferase (HPRT) [NM_013556.2]
forward 5′- GTTAAGCAGTACAGCCCCAAA -3′ and
reverse 5′- AGGGCATATCCAACAACAAACTT -3′
were kindly provided by Dr. Xue Luo (Department of
Tropical Physiology and Pathology, Institute of Tropical
Medicine, Third Military Medical University, China). The
PCR reaction conditions were as follows: 3 min at 95 °C
for activation, 40 cycles of 3 s at 95 °C, and 20 s at 59 °C
for COX-2, mPGES-1, and HPRT or at 63 °C for EP2 and
HPRT, followed by 60–95 °C melt. The relative expression
levels of COX-2 and mPGES-1 messenger RNAs (mRNAs)
were normalized to an internal control HPRT using the
2−ΔΔCt cycle threshold method [34].
Immunoblot analysis
Cells were washed with ice-cold PBS and scraped in
RIPA lysis buffer containing protease and phosphatase
inhibitors (Roche, Penzberg, Germany). Whole-cell ex-
tracts (80 μg/lane) were separated using 10 or 12%
SDS-polyacrylamide gel and then transferred onto PVDF
membranes (Bio-Rad, Hercules, CA, USA). The mem-
branes were blocked in PBS with 5% non-fat milk for
1 h and then incubated with their respective primary
antibodies against COX-2 (1:200; Cayman Chemical),
mPGES-1 (1:80; Santa Cruz Biotechnology, Santa Cruz,
USA), and EP2 (1:200; Cayman Chemical), and with
antibodies purchased from Cell Signaling Technology
(Danvers, MA, USA) that recognize phospho-JAK2
Tyr-1007/1008 (p-JAK2, 1:1000), JAK2 (1:1000), phospho-
STAT3 Tyr705 (p-STAT3, 1:1000), STAT3 (1:1000),
phospho-p38 MAPK Thr180/Tyr182 (p38, 1:800), p38
MAPK (1:500), phospho-p44/42 MAPK (Erk1/2) Thr202/
Tyr204 (1:1000), p44/42 MAPK (Erk1/2) (1:800), phos-
pho-SAPK/JNK Thr183/Tyr185 (1:300), and SAPK/JNK
(1:1000). The membranes were washed four times for
5 min each in Tris-buffered saline Tween-20 (TBST) and
then incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (ZsBio) for 1 h at room
temperature. After incubation, the membranes were reacted
with enhanced chemiluminescence reagent (Bio-Rad), and
the signal was detected using a ChemiDoc MP gel imaging
system (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH, 1:1000; Cell Signaling Technology) was used
as an internal control. Relative band densities were
determined by densitometric analysis using Image Lab
software (Bio-Rad).
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Statistical analysis
Statistical analyses were performed using SPSS software.
Each experiment was repeated a minimum of three times,
and the data are expressed as the means ± SEM. The nor-
mality of the data were verified by the Kolmogorov-
Smirnov test before further analysis. Significant differences
between the groups were assessed by a one- or two-way
ANOVA followed by Tukey’s test. Statistical significance
was established at P < 0.05.
Results
Effect of EMF exposure on the phagocytosis of 647-fAβ42
in N9 cells
The fibril form of fluorescent-labeled Aβ is commonly
used to mimic late-stage AD to investigate Aβ clearance
[17, 35]. Given that Aβ42 fibrils enhance microglial
phagocytic ability [8, 17, 18], low levels of fAβ42 and a
strong fluorescent signal label HiLyte™ Fluor 647 were used
in our experimental conditions. At a low concentration of
0.1 μg/ml, 647-fAβ42 was shown to be continuously
engulfed within 3 h in the cultured medium (Fig. 1a). To
avoid the probable duration and degradation of 647-fAβ42,
a short 1-h phagocytic process was considered appropriate
and was performed after EMF exposure in the following ex-
periments. EMF was not found to cytotoxic to N9 cells
24 h after the 20-min exposure period (Additional file 1:
Figure S1a). EMF resulted in decreased phagocytosis of
647-fAβ42 in the N9 cells after EMF exposure, as esti-
mated via FACS (Fig. 1b). Compared to the phagocytic
ratio in the sham exposure control cells (normalized to
100%), the ratio was slightly lower in cells at 3 h (94%)
after EMF treatment, but the ratio decreased to 42% at
12 h after of EMF exposure (Fig. 1b). A similar result
was observed via confocal microscopy, for which the
fluorescence intensity was significantly decreased 12 h
after EMF exposure (Fig. 1b, c). These findings suggest
that EMF may be a potential risk factor for Aβ
clearance in AD.
Fig. 1 Flow cytometry and confocal microscopy analyses of the effect of EMF exposure on phagocytic capacity in N9 cells. N9 cells were exposed
to 2.45-GHz EMF for 20 min. Untreated cultures were used as sham-exposed controls. N9 cells were subjected to a 1-h process of phagocytosis of
fAβ42 with a strong fluorescent signal label HiLyte™ Fluor 647 (647-fAβ42) at the indicated time points after EMF exposure. a Continuous engulfment of
647-fAβ42 within 3 h in N9 cells. b Normalized average fluorescence intensity of 647-fAβ42 ingested per group estimated using a flow cytometer and a
confocal microscope. *P < 0.05 vs the sham-exposed control group. c Microscopy images of 647-fAβ42 phagocytosis in N9 cells 3 and 12 h after EMF
exposure. Scale bar= 20 μm
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Induction of COX-2-PGE2 synthesis is associated with
phagocytic depression in EMF-stimulated N9 cells
Given the neuropathological features of AD, including
the hallmark amounts of fAβ42 and PGE2 production
[11–14], we examined the levels of PGE2 production in
cell culture medium supernatants at the indicated times
after EMF exposure. We found that the secretion of
PGE2 was quite low in the sham-exposed control cells
(Fig. 2a). EIA indicated that EMF exposure resulted in
robust PGE2 release in a time-dependent manner and
reached a maximum at 12 h (Fig. 2a). To investigate
whether the induction effect of EMF on PGE2 release
was related to the COX-2 and mPGES-1 enzymes, we
determined the expressions of COX-2 and mPGES-1
and the production of PGE2 with or without the pre-
treatment with the selective COX-2 inhibitor celecoxib
(1, 5, and 25 μM) in EMF-stimulated N9 cells. The pro-
duction of PGE2 dramatically decreased in N9 cells cul-
tured with celecoxib in a dose-dependent manner 12 h
after EMF exposure (Fig. 2a). Furthermore, qRT-PCR
and western blotting analysis showed that the levels of
COX-2 and mPGES-1 were significantly increased 12 h
after EMF exposure, and these increases could be
suppressed by celecoxib pre-conditioning (Fig. 2c, d).
We then tested whether the higher PGE2 release was asso-
ciated with phagocytic depression after EMF exposure.
Fig. 2 Improvement in phagocytic ability for EMF-exposed N9 cells with the addition of celecoxib. N9 cells were pretreated with or without
celecoxib (1, 5, and 25 μM) for 30 min and then exposed to 2.45-GHz EMF (+) or sham exposed (−) for 20 min. Then, cells were subjected to a
1-h process of phagocytosis of 647-fAβ42 at the indicated time points after EMF exposure. a Enzyme immunoassay of PGE2 production in N9
cells pretreated with or without celecoxib 3 and 12 h after EMF exposure. b Normalized average fluorescence intensity of 647-fAβ42 ingested
per group 12 h after EMF exposure estimated using a flow cytometer and a confocal microscope. For a and b, *P < 0.05 vs the sham-exposed
control group; #P < 0.05 vs the EMF-exposed group. c Microscopy images of 647-fAβ42 phagocytosis in N9 cells pretreated with or without celecoxib
12 h after EMF exposure. Scale bar = 20 μm
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The normalized phagocytic ratio was restored according
to the concentration of celecoxib (1, 5, and 25 μM) for
cells exposed to EMF compared with the sham-exposed
controls (Fig. 2b, c), for which the phagocytic ratios were
46, 63, and 89%, respectively (Fig. 2b). Our findings con-
firm that EMF exposure can reduce phagocytosis of fAβ42
but that inhibition of PGE2 release using celecoxib can
compensate for the reduction. These results indicated the
involvement of PGE2 in the impaired microglial phagocyt-
osis of fibrillar Aβ42 in response to EMF stimulation.
Inhibition of STAT3- and MAPK-dependent PGE2 synthesis
and phagocytic depression in EMF-stimulated N9 cells
To further analyze the candidate upstream signaling of
COX-2-derived PGE2 synthesis, we first tested whether
JAK2-STAT3 and MAPK signaling pathways are in-
volved in the immunomodulatory action of PGE2 in
EMF-stimulated N9 cells. Western blot analysis indicated
significant phosphorylation of these signaling molecules in
N9 cells after EMF exposure (Fig. 3a–e). It was also found
that the cells treated with only the selective inhibitors
of JAK2, STAT3, and MAPKs exhibited no change in
phagocytic ability (Fig. 4a). Compared to the low phagocytic
ratio of EMF-exposed N9 cells, depressed phagocytosis was
abolished when the EMF-exposed N9 cells were pretreated
with JAK2 inhibitor AG490, STAT3 inhibitor S3I-201, p38
inhibitor SB203580, MEK1/2-ERK1/2 inhibitor PD98059,
and JNK inhibitor SP600125 (Fig. 4a). Not surprisingly, the
production of PGE2 remained at the basal level when the
cells were treated with only each inhibitor (Fig. 4b). In sup-
port of these, other pro-inflammatory factors TNF-α and
NO release were dramatically suppressed by the inhibition
of JAK2-STAT3 pathway in our previous study [30, 31].
In the present study, we also validated the inhibitory ef-
fects of TNF-α and NO production via MAPK inhibi-
tors (Fig. 4c, d). Moreover, AG490, S3I-201, SB203580,
PD98059, and SP600125 abrogated the phosphorylations
of JAK2, STAT3, p38, ERK1/2, and JNK evoked by EMF
stimulation (Fig. 3a–e), leading to the abolishment of
PGE2 up-regulation caused by EMF exposure in N9 cells
(Fig. 4b). We also found a similar suppression of COX-2
and mPGES-1 at mRNA and protein levels in N9 cells for
pre-conditioning with these inhibitors, except for the
mRNA level of mPGES-1 in the SP600125-treated cells,
after EMF exposure (Fig. 5a, b). SP600125 did not signifi-
cantly reduce EMF-induced mPGES-1 mRNA expression
Fig. 3 EMF exposure induces phosphorylation of JAK2, STAT3, and MAPKs in N9 cells. N9 cells were pretreated with or without JAK2 inhibitor
AG490 (25 μM), STAT3 inhibitor S3I-201 (30 μM), p38 inhibitor SB203580 (10 μM), mitogen-activated protein kinase (MEK)-extracellular
signal-regulated kinase (ERK) (MEK1/2-ERK1/2) inhibitor PD98059 (30 μM), c-Jun N-terminal kinase (JNK) inhibitor SP600125 (5 μM), for
30 min and then exposed to 2.45-GHz EMF (+) or sham exposed (−) for 20 min. The phosphorylation and expression of JAK2 (a), STAT3(b),
p38(c), ERK1/2(d), and JNK(e) were determined, and the corresponding densitometric analyses were represented. *P < 0.05 vs the sham-exposed
control group; #P < 0.05 vs the EMF-exposed group
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(Fig. 5a). Interestingly, SP600125 pretreatment led to a
dramatic down-regulation of mPGES-1 protein in EMF-
stimulated N9 cells (Fig. 5b), suggesting that the inhibition
of mPGES-1 by indirect inhibition of JNK might occur at
a post-transcriptional level. Overall, these data suggest
that STAT3 and MAPKs may be the intracellular signal
molecules mediating PGE2 action on phagocytic depres-
sion in EMF-stimulated N9 cells.
EP2 is involved in PGE2-dependent phagocytic depression
in EMF-stimulated N9 cells
In a previous work, PGE2-induced impaired microglial
phagocytosis could be prevented by inhibiting EP recep-
tors [18]. Thus, to identify the central receptor down-
stream of PGE2 signaling, we performed a phagocytosis
assay with selective antagonists of EP1-4 in EMF-
stimulated N9 cells. As shown in Fig. 6a, treatment
with the EP2 antagonist AH6809, but not GW848687X
(an EP1 antagonist), L-798106 (an EP3 antagonist), or
GW627368X (an EP4 antagonist), significantly reversed
the reduction effect of EMF-induced phagocytosis in
N9 cells according to the FACS analysis. Clearly, the
cells treated with AH6809, GW848687X, L-798106, and
GW627368X alone showed no change in phagocytosis
compared to the sham-exposed control cells (Fig. 6a).
Confocal microscopy provided further evidence for the im-
provement in phagocytosis by AH6809 in EMF-treated N9
cells (Fig. 6b). Given the above results, we focused our
studies on activation of the EP2 receptor by inhibiting
COX-2, JAK2, STAT3, and MAPKs in EMF-stimulated N9
cells. We found that EMF exposure significantly increased
the expression of EP2 (Fig. 7a, b). Moreover, the qRT-
PCR and immunoblot analyses revealed that EP2
activation was blocked by celecoxib, AG490, S3I-201,
SB203580, PD98059, and AH6809 in EMF-stimulated
N9 cells (Fig. 7a, b). These results suggest that the
PGE2-EP2 receptor signaling pathway might be involved
in the JAK2-STAT3- and MAPK-mediated phagocytosis
depression in N9 cells after EMF exposure.
Discussion
In the present study, we observed a significant decrease
in microglial phagocytosis of fluorescent-labeled fibrillar
β amyloid (1-42) (647-fAβ42) and a distinct increase in
endogenous PGE2 in N9 cells after EMF exposure. In-
hibition of endogenous PGE2 production by a COX-2
inhibitor celecoxib improved phagocytic ability, which
is consistent with our previous data, indicating that
Fig. 4 Inhibition of JAK2, STAT3, and MAPKs ameliorated the phagocytosis of 647-fAβ42 and abrogated the induction of TNF-α and NO in
EMF-stimulated N9 cells. N9 cells were pretreated with or without celecoxib (25 μM), AG490 (25 μM), S3I-201 (30 μM), SB203580 (10 μM),
PD98059 (30 μM), and SP600125 (5 μM), for 30 min and then exposed to 2.45-GHz EMF or sham exposed for 20 min. Then, cells were subjected to a
1-h process of phagocytosis of 647-fAβ42 12 h after EMF exposure. a Normalized average fluorescence intensity of 647-fAβ42 ingested per group 12 h
after EMF exposure estimated using a flow cytometer. Enzyme immunoassay of PGE2 (b) and TNF-α (c) production and Griess determination of
nitrite (d) in N9 cells pretreated with or without the mentioned pharmacologic compounds of interest 12 h after EMF exposure. *P < 0.05 vs
the sham-exposed control group; #P < 0.05 vs the EMF-exposed group
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exogenous PGE2 depressed the fibrilled synthetic Aβ42-
stimulated microglial phagocytosis of fluorescent-labeled
latex beads [18]. Similar inhibitory regulation of mPGES-1
and COX-2 expressions and PGE2 release was observed
after inhibition of various signaling pathways, including
the JAK2-STAT3 and MAPK signaling cascades. Not sur-
prisingly, these reduction effects due to the blockade of
JAK2-STAT3 and MAPK signaling result in the amelior-
ation of phagocytic ability in EMF-stimulated N9 cells.
The inhibition study of E-prostanoid (EP) 1-4 receptors
revealed evidence of the improvement in phagocytosis by
the EP2 antagonist AH6809 in EMF-treated N9 cells.
These findings are in agreement with other studies that
have reported impaired phagocytosis in PGE2-related
chronic inflammatory environments [11, 16]. Moreover,
the inhibitors of COX-2, JAK2, STAT3, and MAPKs inhib-
ited the expression of EP2. Combined with previous stud-
ies demonstrating that PGE2-EP2 signaling is related to
impaired microglial clearance of Aβ and plaques [36–38],
we suggest that EMF exposure could induce phagocytic
depression via JAK2-STAT3- and MAPK-dependent
PGE2-EP2 receptor signaling pathways in microglia.
It is well known that inflammatory activation of microglia
and Aβ deposition are associated with the progression of
Alzheimer’s disease (AD) [10, 14]. Several epidemiological
and experimental studies have shown that EMF exposure
can induce strong glial reactivity in different brain regions
[39–41]. EMF exposure has also been demonstrated to in-
crease the risk of AD [4, 5]. In a previous work, we demon-
strated that an initial activation and pro-inflammatory
response of microglia is induced by EMF exposure [30, 31].
Under the inflammatory conditions, we further observed
an alteration in the clearance function of EMF-stimulated
N9 cells [9]. Similarly, in this study, we observed an
inversed correlation of pro-inflammatory COX-2 and
prostaglandin expression with attenuated phagocytosis
of 647-fAβ42 in EMF-stimulated N9 cells. In support of
this, down-regulated phagocytosis of latex particles or
apoptotic cells has also been observed in other members of
the mononuclear phagocyte system, such as macrophages
and monocytes, in the presence of static magnetic fields
(SMFs) [42–44]. These decreased phagocytic activities were
concomitant for driving the expressions of molecular
components of various signaling pathways and effector
functions, especially intracellular free Ca2+ ([Ca2+]i), in
the presence of SMFs [42, 44]. In support of this, sev-
eral studies emphasized a possible relationship between
evoked levels of [Ca2+]i and the synthesis of the classical
pro-inflammatory mediator PGE2 [45, 46]. In contrast,
contradictory evidence has indicated a significant increase
Fig. 5 Involvement of JAK2, STAT3, and MAPKs in the regulation of the expression of COX-2 and mPGES-1 in EMF-stimulated N9 cells. N9 cells
were pretreated with or without celecoxib (25 μM), AG490 (25 μM), S3I-201 (30 μM), SB203580 (10 μM), PD98059 (30 μM), and SP600125 (5 μM)
for 30 min and then exposed to 2.45-GHz EMF or sham exposed for 20 min. Relative mRNA (a) and protein (b) levels of COX-2 and mPGES-1 in
N9 cells pretreated with or without the mentioned pharmacologic compounds of interest 12 h after EMF exposure. *P < 0.05 vs the sham-exposed
control group; #P < 0.05 vs the EMF-exposed group
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in the phagocytic uptake of latex beads in macrophages
after a short time of extremely low-frequency EMF
[47, 48]. The heterogeneous regulation of phagocytosis by
EMF may be largely attributed to the different parameters
and times of exposure and to the different types of phago-
cytes, the different degrees of cellular differentiation or ac-
tivation, and perhaps differences in potential inflammatory
conditions. Thus, understanding the molecular pathways
of the pro-inflammatory activation and the alteration of
the clearance function in microglia triggered by EMF
exposure might open new therapeutic options for
suppressing AD development by improving Aβ-related
microglial phagocytosis.
Recent studies have provided increasing evidence for
the microglial pro-inflammatory responses and impaired
microglial capacity of Aβ clearance in the brains of AD
patients [8, 10, 49, 50]. It has been reported that microglia
continue to produce pro-inflammatory cytokines but lose
their Aβ clearance capabilities in a PS1-APP transgenic
mouse model of AD [50]. Treatment with NO-generating
compounds caused impaired phagocytosis in BV-2 micro-
glia, and an inverse correlation between NO production
and phagocytosis was observed upon β-amyloid pretreat-
ment [51]. The addition of TNF-α reduces the expression
of Aβ phagocytosis-related genes and decreases the uptake
of Aβ in N9 cells [50]. Moreover, pro-inflammatory cy-
tokines have been shown to inhibit fAβ-stimulated
phagocytosis of fluorescent microspheres in BV-2 micro-
glia [8]. In addition to down-regulating Aβ clearance path-
ways, pro-inflammatory cytokines (TNF-α, IL-1β, and
Fig. 6 Involvement of EP2 activity in the restoration of impaired phagocytosis of 647-fAβ42 in EMF-stimulated N9 cells. N9 cells were pretreated
with or without PG receptor EP1 antagonist GW848687X (5 μM), EP2 antagonist AH6809 (10 μM), EP3 antagonist L-798106 (10 μM), and EP4
antagonist GW627368X (10 μM). a Normalized average fluorescence intensity of 647-fAβ42 ingested per group 12 h after EMF exposure estimated
using a flow cytometer and a confocal microscope. *P < 0.05 vs the sham-exposed control group; #P < 0.05 vs the EMF-exposed group. b Microscopy
images of 647-fAβ42 phagocytosis in N9 cells pretreated with or without AH6809 12 h after EMF exposure. Scale bar= 20 μm
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interferon-γ) may also contribute to Aβ generation by
up-regulating β-secretase and the active cleavage of APP
[52, 53]. Considering the rapid induction of pro-
inflammatory COX-2 and prostaglandins in the brains of
AD patients [6, 11], we have previously reported the effect
of PGE2 on the phagocytic ability of fAβ42-stimulated N9
cells and demonstrated a significant decrease in fAβ42-ac-
tivated microglial phagocytosis of fluorescent-labeled latex
beads by PGE2 [18]. In the present study, we observed a
significant decrease in the microglial phagocytosis of 647-
fAβ42 and a distinct increase in endogenous PGE2 in N9
cells after EMF exposure compared with the sham-exposed
controls. Moreover, we found that incubation of cultured
N9 cells with the COX-2 inhibitor celecoxib prevented the
expression of mPGES-1 and COX-2, PGE2 release, and
phagocytosis depression induced by EMF exposure.
Taken together, these data suggested that pharmacological
inhibition of the COX-2-PGE2 pathway may help critically
improve microglia-targeted Aβ clearance against electro-
magnetic radiation.
Although PGE2 is of interest as the classic mediator of
the inflammation process [16, 23], knowledge regarding
the exact molecular mechanisms of the upstream regula-
tors of PGE2 that underlie the intricate interplay in
microglial pro-inflammatory responses and microglial
phagocytosis of Aβ following EMF exposure is severely
limited. Theoretically, mPGES-1 and COX-2 have been
implicated in the inflammation-related biosynthetic
pathway of PGE2 production [23]. In the present study,
we validated that EMF exposure significantly increased
mPGES-1 and COX-2 expressions and PGE2 release in
N9 cells, which were accompanied by phagocytosis de-
pression. In addition, uncoupled and heterogeneous pat-
terns of mPGES-1 and COX-2 expressions have been
revealed in LPS-activated primary rat microglia [19, 21].
To reveal the upstream regulators of the COX-2-PGE2
system, we investigated the involvement of the aforemen-
tioned inflammatory pathways. Our results demonstrated
that different inhibitory levels of mPGES-1 and COX-2
mRNA and proteins were observed by pretreatment
with pharmacological inhibitors of JAK2, STAT3, and
MAPKs (p38, MEK1/2-ERK1/2, and JNK) in EMF-
stimulated N9 cells. These inhibition studies also indi-
cated the amelioration of the microglial phagocytosis of
647-fAβ42, reflecting the beneficial effects of JAK2-
STAT3- and MAPK-dependent PGE2 blockages on the
microglial phagocytic capacity after EMF exposure.
Moreover, most previous studies have shown the in-
volvement of the p38, ERK1/2, and JNK MAPK signal-
ing pathways in the release of PGE2 from cultured
Fig. 7 Involvement of COX-2, JAK2, STAT3, and MAPKs in the regulation of the expression of EP2 in EMF-stimulated N9 cells. N9 cells were
pretreated with or without celecoxib (25 μM), AG490 (25 μM), S3I-201 (30 μM), SB203580 (10 μM), PD98059 (30 μM), SP600125 (5 μM), and
AH6809 (10 μM) for 30 min and then exposed to 2.45-GHz EMF or sham exposed for 20 min. Relative mRNA (a) and protein (b) levels of EP2
in N9 cells pretreated with or without the mentioned pharmacologic compounds of interest 12 h after EMF exposure. *P< 0.05 vs the sham-exposed
control group; #P< 0.05 vs the EMF-exposed group
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microglia [19, 20], and macrophages have been shown
to possess similar functional properties [54]. Moreover,
STAT3 signaling was found to be critical in establishing
the pharmacologic function of an active natural compo-
nent, withaferin A, in LPS-induced PGE2 secretion
from BV-2 cells and primary rat microglia [22]. Our
results combined with previous studies suggest that
microglial PGE2-mediated phagocytosis depression in-
duced by EMF exposure is attributable in part to the
activation of STAT3 and MAPK signaling.
As an important pro-inflammatory mediator, PGE2 ex-
erts its actions locally through the binding of four molecu-
larly and biochemically heterogeneous PGE receptors,
termed EP1, EP2, EP3, and EP4 [15]. We previously inves-
tigated the key roles of EP1-4 in mediating PGE2 action in
fAβ42-stimulated N9 cells using their specific agonists and
antagonists, and we confirmed the involvement of EP2 in
the regulation of microglial phagocytosis [18]. In this
study, to reveal the essential role of microglial EP recep-
tors in the action of PGE2-mediated inhibition of phago-
cytosis, we used EP antagonists to assess the improvement
in microglial phagocytosis of 647-fAβ42. We found that
the effect of PGE2 reduction on microglial phagocytosis of
647-fAβ42 appeared to be mainly mediated by EP2 in
EMF-stimulated N9 cells. Our data corroborate other
studies that have attributed microglial EP2 activity to the
reduction of microglial clearance of Aβ and plaques using
receptor-knockout animals [36–38]. Moreover, the
qRT-PCR and immunoblot analyses showed significant
abolishment of EP2 levels by the specific inhibitors of
COX-2, JAK2, STAT3, and MAPKs used in our experi-
mental conditions. Thus, these results suggest a potent
role of JAK2-STAT3- and MAPK-dependent PGE2 in
mediating phagocytosis depression via EP2 receptors in
N9 cells after EMF exposure. Notably, differences exist
between acute in vitro regulation of PGE2-mediated
fAβ42 phagocytosis and chronic in vivo interactions be-
tween endogenous PGE2 and Aβ clearance from the entire
cerebral cortex and hippocampus over several years.
Although the up- and downstream immunomodulatory
modes of PGE2 action and the known side effects have
been widely described, the main pharmaceutical focus on
the specific blockage of PGE2 synthesis and the inhibition
of selected EP receptor activity remain to be solved.
Conclusions
Our data provide detailed information regarding the
intracellular signaling pathways involved in PGE2 syn-
thesis and phagocytosis depression by EMF-activated N9
microglial cells (Fig. 8). Conversely, the selective inhibitors
of JAK2, STAT3, and MAPKs ameliorated microglial
phagocytosis via inhibition of the COX-2-PGE2 pathway.
Simultaneously, these inhibitors attenuated EP2-related
impaired microglial phagocytosis. These results suggest
that JAK2-STAT3- and MAPK-dependent PGE2-EP2
receptor signaling modulates the phagocytosis of fAβ42 in
EMF-stimulated microglia. Further studies targeting the
combined use of pharmacological interventions of PGE2
and EP2 receptors will boost novel therapeutic approaches
for AD and other neurodegenerative diseases.
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